Scantox acquires QPS Neuropharmacology, a CRO specializing in CNS research.

Scantox completes acquisition of QPS Neuropharmacology, a leading drug discovery CRO specializing in neurodegenerative, rare diseases, and mental disorders. The acquisition expands Scantox's value chain coverage and adds unique CNS research capabilities. QPS Neuropharmacology, founded in 1999, has a long history in lead-optimization services and efficacy studies, and employs over 80 people at its 2,700m2 facility in Austria.